| Assessment Status | Rapid Review Complete |
| HTA ID | 24028 |
| Drug | Trastuzumab deruxtecan |
| Brand | Enhertu® |
| Indication | As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. |
| Assessment Process | |
| Rapid review commissioned | 17/07/2024 |
| Rapid review completed | 21/08/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care. |
| Full HTA commissioned by the HSE | 27/08/2024 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.